Trial
NCT03717012
Study of Pulmonary Rehabilitation in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Phase IVTERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Boehringer Ingelheim
Collaborators
—
Condition
Idiopathic Pulmonary Fibrosis
Intervention
Nintedanib
Why stopped
The trial was terminated prematurely due to difficulties with recruitment because of the COVID-19 pandemic.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-06-09